ArticleLipids in health and disease2025
The modified cardiometabolic index versus triglyceride-glucose index in predicting type 2 diabetes incidence: a 12-year cohort study.
Article in Lipids in health and disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Enhancing the accuracy of bioimpedance-derived appendicular skeletal muscle mass in aged adults through machine learning.European geriatric medicine · 2026Article
- Nationwide prospective cohort study in China: the impact of cumulative modified cardiometabolic index on cardiovascular disease incidence.Frontiers in cardiovascular medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundType 2 diabetes (T2D) presents a growing global health burden, with early identification of high-risk individuals remaining a critical challenge. The modified cardiometabolic index (MCMI), which integrates visceral fat, lipid ratios, and glucose measures, has emerged as a promising alternative, offering a more comprehensive assessment of metabolic risk. However, no large-scale cohort study has directly assessed the long-term predictive performance of the MCMI for incident T2D, particularly in normoglycemic populations. This study investigates the 12-year predictive performance of the MCMI for incident T2D and compares its efficacy with that of the triglyceride-glucose (TyG) index.
methodsIn this longitudinal cohort study, 15,453 adults with normal baseline glucose were selected from the NAGALA study. The associations of the MCMI and the TyG index with T2D risk were examined using Cox regression models and restricted cubic spline (RCS) analysis. Predictive performance was compared through receiver operating characteristic (ROC) analysis, and subgroup analyses assessed consistency across different populations.
resultsAmong participants, 373 (2.41%) developed T2D during a mean 6.05-year follow-up. In unadjusted analyses, the TyG index showed an HR of 3.76 (95% CI 3.22–4.38, P < 0.001), while the MCMI demonstrated a stronger association (HR 6.25, 95% CI 5.28–7.40, P < 0.001). These relationships persisted in fully adjusted models. RCS analysis revealed the TyG index and the MCMI maintained a positive linear relationship with T2D risk. ROC analysis indicated superior predictive performance for the MCMI within 1 to 12 years compared to the TyG index and remained relatively consistent in various subgroups.
conclusionsThe MCMI shows a strong, linear association with incident T2D and offers better predictive performance than the TyG index. These findings support the potential clinical utility of the MCMI for T2D risk stratification in normoglycemic individuals. From a broader health system perspective, its application in community-based screening, particularly within underserved regions, may strengthen early detection and support more efficient and accessible preventive care, thereby helping to alleviate the future burden on health systems.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.